We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Lipoxen | LSE:LPX | London | Ordinary Share | GB00B08NWV55 | ORD 0.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 7.875 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMLPX RNS Number : 9059N Lipoxen PLC 21 June 2010 +---------------------------------+---------------------------------+ | FOR IMMEDIATE RELEASE | 21 June 2010 | +---------------------------------+---------------------------------+ Lipoxen plc ('Lipoxen' or 'the Company') Further PolyXenTechnology Patent - PolyXen patent family strengthened and extended into 2025 - Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, announces today that its monofunctional PSA PolyXen technology grant has been allowed. The patent extends the PolyXen technology patent family in the US giving both Lipoxen and its license partners additional patent protection into 2025. The monofunctional PSA technology is similar to Lipoxen's other PolyXen technologies as it enables the attachment of polysialic acid (PSA, a polymer occurring naturally in humans) to a therapeutic protein, thereby extending its active life. This process is known as polysialylation and improves drug performance and longer circulation time of the drug in the body. The resulting conjugate molecules are biodegradable, non-immunogenic and non-toxic, and therefore are expected to avoid the toxicity attributed to other methods of extending active life, such as the use of polyethylene glycol in PEGylated protein drug candidates. Importantly, this new patent means that Lipoxen's PolyXen patent family now covers the creation of therapeutic conjugates utilising both the reducing end, as well as the non-reducing end, such methodologies having been shown in tests completed prior to both pre-clinical studies and clinical trials to avoid the problem of side product contamination. Commenting on the patent grant, M. Scott Maguire, CEO of Lipoxen, said: "This new PolyXen technology patent will protect Lipoxen's novel polysialylationtechnology into 2025. By applying this novel technology to its partners' therapeutic proteins, it is in the unique position delivering the benefits of polysialylation such as extending its active life plus the advantage of avoiding final product contamination. This forms an important part of Lipoxen's strategy to build its patent portfolio and secure long term value in the US, world's largest pharmaceutical market." - Ends - For further information, please contact: Enquiries +------------------------------------------+--------------------+ | Lipoxen plc | +44 (0)20 7389 | | | 5015 | +------------------------------------------+--------------------+ | M. Scott Maguire, Chief Executive | | | Officer | | +------------------------------------------+--------------------+ | | | +------------------------------------------+--------------------+ | Singer Capital Markets (nominated | +44 (0)20 3205 | | adviser) | 7500 | +------------------------------------------+--------------------+ | Jeff Keating / Claes Spång | | +------------------------------------------+--------------------+ | | | +------------------------------------------+--------------------+ | Buchanan Communications | +44 (0)20 7466 | | | 5000 | +------------------------------------------+--------------------+ | Lisa Baderoon, Catherine Breen | | +------------------------------------------+--------------------+ About Lipoxen Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines. Lipoxen has three proprietary patented technology platforms: 1) PolyXen - for extending the efficacy and half life of biologic drugs 2) ImuXen - for creating new vaccines and improving existing vaccines 3) SiRNAblate - for the delivery of siRNA Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its products. Lipoxen has multiple drug and vaccine programmes in development. Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes vaccines against HIV, influenza and malaria and an exclusive license deal with Baxter Healthcare for blood coagulation drugs. The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities. Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and management led the GBP2.9 million fundraising that the Company announced in May 2009. This fundraising was followed up by a GBP1.2 million placing in April 2010 which was led by the Company's management team. Lipoxen, which was founded in 1997, trades on the AIM Market of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website: www.lipoxen.com. This information is provided by RNS The company news service from the London Stock Exchange END MSCEVLFFBQFZBBL
1 Year Lipoxen Chart |
1 Month Lipoxen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions